Status: Recruiting
A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.
Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Amplified Sciences IncUpdated: Mar 16, 2026Locations: 3Duration: 12 Months
Eligibility criteria
Patients 18 years of age or older [+3]
Patients diagnosed with pancreatic cancer. [+3]